dal-GenE-2

Objective

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The DAL-302 (dal-GenE-2) trial.

Research Study Categories

• Adult Research Studies

Specialties

• Cardiology

Contact

Cardiology Clinical Trials at 866-839-4128, [email protected]